Advertisement
Advertisement
Rinvask

Rinvask

pitavastatin

Manufacturer:

Yarindo Farmatama
Concise Prescribing Info
Contents
Pitavastatin Ca
Indications/Uses
Primary hyperlipidemia & mixed dyslipidemia. Heterozygous familial hypercholesterolemia (HeFH).
Dosage/Direction for Use
1-4 mg once daily. Initial dose: 2 mg. Max daily dose: 4 mg. Patients w/ moderate & severe renal impairment (GFR 30-59 mL/min/1.73 m2 & 15-29 mL/min/1.73 m2) w/o hemodialysis, ESRD on hemodialysis Initially 1 mg once daily. Max: 2 mg once daily.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Patients w/ liver diseases. Concomitant use w/ cyclosporin. Pregnancy & lactation.
Special Precautions
Patients w/ predisposing factors for myopathy (ie, kidney dysfunction, untreated hypothyroidism). Discontinue treatment if creatine kinase increases or any suspected or diagnosed myopathy. Perform liver enzyme tests before treatment or if any liver damage occurs. Excessive alcohol consumption. Elderly ≥65 yr.
Adverse Reactions
Rhabdomyolysis w/ myoglobinuria, acute kidney failure, myopathy.
Drug Interactions
Concomitant use w/ cyclosporin, erythromycin, rifampicin, gemfibrozil, other fibrates, niacin.
MIMS Class
Dyslipidaemic Agents
ATC Classification
C10AA08 - pitavastatin ; Belongs to the class of HMG CoA reductase inhibitors. Used in the treatment of hyperlipidemia.
Presentation/Packing
Form
Rinvask FC tab 2 mg
Packing/Price
3 × 10's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement